Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of eplontersen in transthyretin-mediated amyloid cardiomyopathy
2022-502415-11-00Phase 3Authorised
- Sponsor
- Ionis Pharmaceuticals
- Start
- May 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of eplontersen in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Ionis Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events and Safety laboratory assessments over time. Planned start May 2023; status: authorised.
02
Drugs
eplontersen
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2022-502415-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502415-11-00.